开放性眼球外伤玻璃体视网膜手术中辅助使用曲安奈德随机对照试验:ASCOT研究
ASCOT研究为3期多中心双盲随机对照试验,纳入280例开放性眼外伤后行玻璃体切除术的患者,比较玻璃体内及Tenon囊下注射曲安奈德与标准治疗的疗效。主要结局6个月最佳矫正视力提高≥10个ETDRS字母的比例治疗组46.9% vs 对照组43.4%,差异无统计学意义;部分次要结局中治疗组视网膜及黄斑完全复位率低于对照组。结论为不推荐该辅助治疗。
要点
- 6个月视力提高≥10个ETDRS字母比例:治疗组46.9%(61/130)vs 对照组43.4%(56/129),差异3.5%(95%CI -8.6%至15.6%),OR=1.03(95%CI 0.61至1.75),p=0.908。
- 稳定完全视网膜复位率治疗组51.6%(65/126)vs 对照组64.2%(79/123),OR=0.59(95%CI 0.36至0.99),治疗组更差。
- 稳定完全黄斑复位率治疗组54.0%(68/126)vs 对照组66.7%(82/123),OR=0.59(95%CI 0.35至0.98),治疗组更差。
核心结论
- 不推荐在开放性眼外伤玻璃体切除术后联合玻璃体内及Tenon囊下注射曲安奈德作为辅助治疗。
研究设计与样本
- 3期、多中心、双盲随机对照试验,纳入开放性眼外伤后行玻璃体切除术的患者,比较辅助曲安奈德(玻璃体内及Tenon囊下注射)与标准治疗,研究期为2014年至2020年。
- 共随机280例患者,历时75个月,其中259例完成研究。
主要发现
- 主要结局6个月最佳矫正视力提高≥10个ETDRS字母的比例:治疗组46.9%(61/130)vs 对照组43.4%(56/129),差异3.5%(95%CI -8.6%至15.6%),OR=1.03(95%CI 0.61至1.75),p=0.908。
- 次要结局指标也未显示治疗获益。
- 稳定完全视网膜复位率治疗组51.6%(65/126)vs 对照组64.2%(79/123),OR=0.59(95%CI 0.36至0.99),治疗组更差。
- 稳定完全黄斑复位率治疗组54.0%(68/126)vs 对照组66.7%(82/123),OR=0.59(95%CI 0.35至0.98),治疗组更差。
临床怎么用
- 原文结论为不推荐联合玻璃体内及Tenon囊下注射曲安奈德作为开放性眼外伤玻璃体切除术的辅助治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND/AIMS: To investigate the clinical effectiveness of adjunctive triamcinolone acetonide (TA) given at the time of vitreoretinal surgery following open globe trauma (OGT). METHODS: A phase 3, multicentre, double-masked randomised controlled trial of patients undergoing vitrectomy following OGT comparing adjunctive TA (intravitreal and subtenons) against standard care (2014-2020). The primary outcome was the proportion of patients with at least 10 Early Treatment Diabetic Retinopathy Study (ETDRS) letter improvement in corrected visual acuity (VA) at 6 months. Secondary outcomes included: change in ETDRS, retinal detachment (RD) secondary to PVR, retinal reattachment, macular reattachment, tractional RD, number of operations, hypotony, elevated intraocular pressure and quality of life. RESULTS: 280 patients were randomised over 75 months, of which 259 completed the study. 46.9% (n=61/130) of patients in the treatment group had a 10-letter improvement in VA compared with 43.4% (n=56/129) of the control group (difference 3.5% (95% CI -8.6% to 15.6%), OR=1.03 (95% CI 0.61 to 1.75), p=0.908)). Secondary outcome measures also failed to show any treatment benefit. For two of the secondary outcome measures, stable complete retinal and macular reattachment, outcomes were worse in the treatment group compared with controls, respectively, 51.6% (n=65/126) vs 64.2% (n=79/123), OR=0.59 (95% CI 0.36 to 0.99), and 54.0% (n=68/126) vs 66.7% (n=82/123), OR=0.59 (95% CI 0.35 to 0.98), for TA vs control. CONCLUSION: The use of combined intraocular and sub-Tenons capsule TA is not recommended as an adjunct to vitrectomy surgery following OGT. TRIAL REGISTRATION NUMBER: NCT02873026.
引用
- Casswell EJ, Cro S, Cornelius VR, et al. Randomised controlled trial of adjunctive triamcinolone acetonide in eyes undergoing vitreoretinal surgery following open globe trauma: The ASCOT study. Br J Ophthalmol. 2024. PMID: 36849205. doi:10.1136/bjo-2022-322787
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。